| Date | Title | Description |
| 22.10.2024 | Camurus provides regulatory update on the US NDA for CAM2029 in acromegaly | Camurus provides regulatory update on the US NDA for CAM2029 in acromegaly
Tue, Oct 22, 2024 01:00 CET Report this content
The FDA issues a Complete Response Letter for CAM2029 pending FDA’s assessment of responses from a third-party manufa... |
| 30.09.2024 | Change in number of shares and votes in Camurus | Change in number of shares and votes in Camurus
Mon, Sep 30, 2024 07:00 CET Report this content
Lund, Sweden — 30 September 2024 — During September 2024, a total of 171,850 employee stock options in Camurus’ employee stock options program E... |
| 21.09.2024 | Camurus Takes a Step Forward in Rare Disease Treatment with Octreotide SC Depot | In the world of pharmaceuticals, breakthroughs often emerge from the shadows of rare diseases. Camurus, a Swedish biopharmaceutical company, is making waves with its recent positive opinion from the European Medicines Agency (EMA) regarding... |
| 20.09.2024 | EMA positive opinion for orphan drug designation to Camurus’ octreotide SC depot for the treatment of polycystic liver disease | EMA positive opinion for orphan drug designation to Camurus’ octreotide SC depot for the treatment of polycystic liver disease
Fri, Sep 20, 2024 08:00 CET Report this content
Lund, Sweden — 20 September 2024 — Camurus (NASDAQ STO: CAMX) tod... |
| 19.09.2024 | Exercise in Camurus’ employee stock options program 2021/2024 | Exercise in Camurus’ employee stock options program 2021/2024
Thu, Sep 19, 2024 15:30 CET Report this content
Lund, Sweden — 19 September 2024 — During September 2024, a total of 142,300 options in Camurus AB’s employee stock options progra... |
| 16.07.2024 | Camurus’ Interim Report Second Quarter 2024 | Camurus’ Interim Report Second Quarter 2024
Tue, Jul 16, 2024 07:00 CET Report this content
“High sales growth and strong financial performance in the second quarter”
Summary second quarter 2024
April - June Total revenues amounted to SEK 4... |
| 15.07.2024 | Camurus announces positive Phase 3 results from the ACROINNOVA 2 study of octreotide SC depot (CAM2029) in acromegaly patients | Camurus announces positive Phase 3 results from the ACROINNOVA 2 study of octreotide SC depot (CAM2029) in acromegaly patients
Mon, Jul 15, 2024 07:30 CET Report this content
Treatment well tolerated with a safety profile consistent with st... |
| 28.06.2024 | Change in number of shares and votes in Camurus | Change in number of shares and votes in Camurus
Fri, Jun 28, 2024 07:00 CET Report this content
Lund, Sweden — 28 June 2024 — During June 2024, 675,300 employee stock options in Camurus’ employee stock options program ESOP 2021/2024 have be... |
| 25.06.2024 | New publication shows effectiveness data for weekly and monthly buprenorphine injections in treating opioid dependence in individuals using fentanyl | New publication shows effectiveness data for weekly and monthly buprenorphine injections in treating opioid dependence in individuals using fentanyl
Tue, Jun 25, 2024 17:00 CET Report this content
Lund, Sweden — 25 June 2024 — Camurus (NASD... |
| 12.06.2024 | Exercise of Camurus’ employee stock options program 2021/2024 | Exercise of Camurus’ employee stock options program 2021/2024
Wed, Jun 12, 2024 16:15 CET Report this content
Lund, Sweden — 12 June 2024 — As of 12 June 2024, a total of 673,200 options in Camurus AB’s employee stock options program (ESOP)... |
| 30.05.2024 | Camurus’ Board of Directors exercises authorization for repurchase of shares for the purpose of securing the company’s commitments under the Performance Share Plan 2024/2027 | Camurus’ Board of Directors exercises authorization for repurchase of shares for the purpose of securing the company’s commitments under the Performance Share Plan 2024/2027
Thu, May 30, 2024 10:00 CET Report this content
Lund, Sweden — 30 ... |
| 28.05.2024 | Camurus to present at Jefferies 2024 Healthcare Conference New York | Camurus to present at Jefferies 2024 Healthcare Conference New York
Tue, May 28, 2024 10:00 CET Report this content
Lund, Sweden — 28 May 2024 — Camurus (NASDAQ STO: CAMX) announces that Fredrik Tiberg, President and CEO, is presenting at t... |
| 23.05.2024 | Camurus receives EMA acceptance of MAA filing for octreotide SC depot (CAM2029) for the treatment of acromegaly | Camurus receives EMA acceptance of MAA filing for octreotide SC depot (CAM2029) for the treatment of acromegaly
Thu, May 23, 2024 11:30 CET Report this content
Lund, Sweden — 23 May 2024 — Camurus (NASDAQ STO: CAMX) today announced that the... |
| 08.05.2024 | Resolutions at the annual general meeting 2024 in Camurus | Resolutions at the annual general meeting 2024 in Camurus
Wed, May 08, 2024 19:00 CET Report this content
Lund, Sweden — 8 May 2024 — Camurus AB’s (CAMX) annual general meeting 2024 was held today, Wednesday 8 May, at Elite Hotel Ideon in L... |
| 08.05.2024 | Camurus’ Interim Report January-March 2024 | Camurus’ Interim Report January-March 2024
Wed, May 08, 2024 07:00 CET Report this content
“Increased profitability and strong operational performance”
Summary first quarter 2024
January - March Total revenues amounted to SEK 390 (284) mill... |
| 02.04.2024 | Notice of annual general meeting 2024 in Camurus (publ) | Notice of annual general meeting 2024 in Camurus (publ)
Tue, Apr 02, 2024 08:00 CET Report this content
The shareholders of Camurus AB (publ), Reg. No 556667-9105, are hereby invited to the Annual General Meeting (“AGM”) on 8 May 2024 at 17... |
| 28.03.2024 | Camurus Annual Report for 2023 | Camurus Annual Report for 2023
Thu, Mar 28, 2024 10:00 CET Report this content
Lund, Sweden — 28 March 2024 — Camurus (CAMX) today announces that the Annual Report for 2023 now is available at the company’s website: www.camurus.com, and as ... |
| 12.03.2024 | Opioid Use Disorder Market to Reach USD 6.15 Billion by 2030, Driven by Growing Focus on Addiction Treatment | Opioid Use Disorder (OUD) Market
Opioid Use Disorder Market Analysis, Industry Trends and Growth Outlook AUSTIN, TEXAS, UNITED STATES, March 12, 2024 /EINPresswire.com/ -- The global opioid use disorder market is experiencing significant gr... |
| 05.03.2024 | Camurus announces FDA acceptance of NDA submission for Oclaiz™ for treatment of acromegaly | Camurus announces FDA acceptance of NDA submission for Oclaiz™ for treatment of acromegaly
Tue, Mar 05, 2024 07:00 CET Report this content
Prescription Drug User Fee Act date (PDUFA) set to 21 October 2024
Lund, Sweden — 5 March 2024 — Camu... |
| 15.02.2024 | Camurus’ Full Year Report 2023 | Camurus’ Full Year Report 2023
Thu, Feb 15, 2024 07:00 CET Report this content
“An excellent fourth quarter with significant growth and pipeline progress”
Fourth quarter and full year summary
October - December Total revenues amounted to SE... |
| 13.02.2024 | Camurus appoints Behshad Sheldon as President of Camurus Inc. | Camurus appoints Behshad Sheldon as President of Camurus Inc.
Tue, Feb 13, 2024 08:00 CET Report this content
Lund, Sweden — 13 February 2024 — Camurus AB (NASDAQ STO: CAMX) today announced the appointment of Behshad Sheldon as President of... |
| 08.02.2024 | Completed enrollment in the POSITANO study of CAM2029 in patients with polycystic liver disease | Completed enrollment in the POSITANO study of CAM2029 in patients with polycystic liver disease
Thu, Feb 08, 2024 08:00 CET Report this content
Lund, Sweden — 8 February 2024 — Camurus (NASDAQ STO: CAMX) today announces completed enrollment... |
| 31.01.2024 | Change in number of shares and votes in Camurus | Change in number of shares and votes in Camurus
Wed, Jan 31, 2024 07:00 CET Report this content
Lund, Sweden — 31 January 2024 — As previously announced, Camurus has carried out a directed share issue. The directed share issue has resulted ... |
| 29.12.2023 | Change in number of shares and votes in Camurus | Change in number of shares and votes in Camurus
Fri, Dec 29, 2023 07:00 CET Report this content
Lund, Sweden — 29 December 2023 — During December 2023, 84,800 subscription warrants in Camurus’ subscription warrant series TO2020/2023 have be... |
| 21.12.2023 | Camurus submits New Drug Application to the US FDA for Oclaiz™ for treatment of acromegaly | Camurus submits New Drug Application to the US FDA for Oclaiz™ for treatment of acromegaly
Thu, Dec 21, 2023 14:00 CET Report this content
Lund, Sweden — 21 December 2023 — Camurus (NASDAQ STO: CAMX) today announced the submission of a New ... |
| 20.12.2023 | Camurus to enter Large Cap segment on Nasdaq Stockholm | Camurus to enter Large Cap segment on Nasdaq Stockholm
Wed, Dec 20, 2023 13:45 CET Report this content
Lund, Sweden — 20 December 2023 — Camurus (NASDAQ STO: CAMX) today announced that the company will be moved from the Mid Cap to the Large... |
| 14.12.2023 | Camurus announces completed enrollment in the Phase 3 SORENTO study of CAM2029 in patients with neuroendocrine tumors | Camurus announces completed enrollment in the Phase 3 SORENTO study of CAM2029 in patients with neuroendocrine tumors
Thu, Dec 14, 2023 08:00 CET Report this content
Lund, Sweden — 14 December 2023 — Camurus (NASDAQ STO: CAMX) today announc... |
| 09.11.2023 | Camurus’ Interim Report Third Quarter 2023 | Camurus’ Interim Report Third Quarter 2023
Thu, Nov 09, 2023 07:00 CET Report this content
“Strong financial performance and launch of Brixadi™ in the US”
Third quarter summary 2023
July - September Total revenues amounted to SEK 384 (241) ... |
| 01.11.2023 | Camurus to present at Jefferies 2023 Healthcare Conference London | Camurus to present at Jefferies 2023 Healthcare Conference London
Wed, Nov 01, 2023 08:00 CET Report this content
Lund, Sweden — 1 November 2023 — Camurus (Nasdaq Stockholm; CAMX), a commercial-stage pharmaceutical company developing innova... |
| 23.10.2023 | Camurus raises financial guidance for the full year 2023 | Camurus raises financial guidance for the full year 2023
Mon, Oct 23, 2023 17:45 CET Report this content
Lund — 23 October 2023 — Camurus today announced revised full year 2023 outlook for the company’s total revenues and profit before taxe... |
| 18.10.2023 | Camurus’ Nomination Committee appointed for the Annual General Meeting 2024 | Camurus’ Nomination Committee appointed for the Annual General Meeting 2024
Wed, Oct 18, 2023 07:00 CET Report this content
Lund — 18 October 2023 — Camurus today announced that the Nomination Committee for the Annual General Meeting (AGM),... |
| 26.09.2023 | Camurus establishes new, sustainable headquarters and laboratories in Science Village, Lund | Camurus establishes new, sustainable headquarters and laboratories in Science Village, Lund
Tue, Sep 26, 2023 11:00 CET Report this content
Lund, Sweden — 26 September 2023 — Camurus AB (NASDAQ STO: CAMX) today announces that the company is... |
| 05.09.2023 | Camurus announces US launch of Brixadi™ for the treatment of moderate to severe opioid use disorder by Braeburn | Camurus announces US launch of Brixadi™ for the treatment of moderate to severe opioid use disorder by Braeburn
Tue, Sep 05, 2023 14:00 CET Report this content
Lund, Sweden — 5 September 2023 — Camurus (NASDAQ STO: CAMX) today announces tha... |
| 31.08.2023 | Change in number of shares and votes in Camurus | Change in number of shares and votes in Camurus
Thu, Aug 31, 2023 07:00 CET Report this content
Lund, Sweden — 31 August 2023 — During August 2023, 80,325 subscription warrants in Camurus’ subscription warrant series TO2020/2023 have been e... |
| 25.08.2023 | Exercise of Camurus’ subscription warrant program 2020/2023 | Exercise of Camurus’ subscription warrant program 2020/2023
Fri, Aug 25, 2023 07:00 CET Report this content
Lund, Sweden — 25 August 2023 — During August 2023, a total of 80,325 subscription warrants in Camurus AB’s warrant program 2020/202... |
| 18.07.2023 | Camurus’ Interim Report Second Quarter 2023 | Camurus’ Interim Report Second Quarter 2023
Tue, Jul 18, 2023 07:00 CET Report this content
“Outstanding second quarter with strong revenue growth, record result, FDA approval and positive phase 3 results”
Second quarter summary
April - Jun... |
| 17.07.2023 | Camurus announces new Phase 3 data reinforcing long-term safety and efficacy of octreotide SC depot (CAM2029) in patients with acromegaly | Camurus announces new Phase 3 data reinforcing long-term safety and efficacy of octreotide SC depot (CAM2029) in patients with acromegaly
Mon, Jul 17, 2023 07:00 CET Report this content
Favorable safety profile and effective biochemical con... |
| 20.06.2023 | Camurus’ octreotide SC depot (CAM2029) achieves superior treatment response compared to placebo in Phase 3 acromegaly trial | Camurus’ octreotide SC depot (CAM2029) achieves superior treatment response compared to placebo in Phase 3 acromegaly trial
Tue, Jun 20, 2023 07:30 CET Report this content
Primary and key secondary endpoints met for once monthly octreotide ... |
| 31.05.2023 | Change in number of shares and votes in Camurus | Change in number of shares and votes in Camurus
Wed, May 31, 2023 07:00 CET Report this content
Lund, Sweden — 31 May 2023 — During May 2023, 35,450 subscription warrants in Camurus’ subscription warrant series TO2020/2023 have been exercis... |
| 29.05.2023 | Camurus to present at Jefferies 2023 Healthcare Conference New York | Camurus to present at Jefferies 2023 Healthcare Conference New York
Mon, May 29, 2023 10:00 CET Report this content
Lund, Sweden — 29 May 2023 — Camurus (Nasdaq Stockholm; CAMX) announces that Fredrik Tiberg, President and CEO, will present... |
| 23.05.2023 | Camurus announces FDA approval of Brixadi™ for the treatment of moderate to severe opioid use disorder | Camurus announces FDA approval of Brixadi™ for the treatment of moderate to severe opioid use disorder
Tue, May 23, 2023 20:30 CET Report this content
Brixadi is the first treatment for opioid use disorder in the US with both weekly and mon... |
| 10.05.2023 | Resolutions at the annual general meeting 2023 in Camurus | Resolutions at the annual general meeting 2023 in Camurus
Wed, May 10, 2023 19:00 CET Report this content
Lund, Sweden — 10 May 2023 — Camurus AB’s (CAMX) annual general meeting 2023 was held today, Wednesday 10 May, at Elite Hotel Ideon in... |
| 10.05.2023 | Camurus’ Interim Report January-March 2023 | Camurus’ Interim Report January-March 2023
Wed, May 10, 2023 07:00 CET Report this content
“A strong quarter with solid organic growth, both top and bottom line”
Summary first quarter 2023
January – March Total revenues amounted to SEK 284 ... |
| 04.04.2023 | Camurus appoints Alberto Pedroncelli as Chief Medical Officer | Camurus appoints Alberto Pedroncelli as Chief Medical Officer
Tue, Apr 04, 2023 14:00 CET Report this content
Camurus appoints Alberto Pedroncelli as Chief Medical Officer
Lund, Sweden — 4 April 2023 — Camurus AB (NASDAQ STO: CAMX) today an... |
| 04.04.2023 | Notice of annual general meeting 2023 in Camurus AB (publ) | Notice of annual general meeting 2023 in Camurus AB (publ)
Tue, Apr 04, 2023 08:00 CET Report this content
The shareholders of Camurus AB (publ), Reg. No 556667-9105, are hereby invited to the Annual General Meeting (“AGM”) on 10 May 2023 a... |
| 30.03.2023 | Camurus Annual Report for 2022 | Camurus Annual Report for 2022
Thu, Mar 30, 2023 10:00 CET Report this content
Lund, Sweden — 30 March 2023 — Camurus (CAMX) today announces that the Annual Report for 2022 now is available at the company’s website: www.camurus.com, and as ... |
| 14.02.2023 | Camurus’ Full Year Report 2022 | Camurus’ Full Year Report 2022
Tue, Feb 14, 2023 07:00 CET Report this content
“First profitable year for Camurus driven by strong sales growth”
Fourth quarter and full year summary
October – December Total revenues amounted to SEK 268 (183... |
| 13.02.2023 | Camurus withdraws variation application for CAM2038 to include chronic pain | Camurus withdraws variation application for CAM2038 to include chronic pain
Mon, Feb 13, 2023 14:00 CET Report this content
Lund, Sweden — 13 February 2023 — Camurus (NASDAQ STO: CAMX) announced today that it has notified the European Medic... |
| 30.12.2022 | Change in number of shares and votes in Camurus | Change in number of shares and votes in Camurus
Fri, Dec 30, 2022 07:00 CET Report this content
Lund, Sweden — 30 December 2022 — During December 2022, 39,596 subscription warrants in Camurus’ subscription warrant series TO2019/2022 have be... |
| 08.12.2022 | Camurus announces PDUFA date for Brixadi™ NDA for the treatment of opioid use disorder in the US | Camurus announces PDUFA date for Brixadi™ NDA for the treatment of opioid use disorder in the US
Thu, Dec 08, 2022 23:00 CET Report this content
Prescription Drug User Fee Act (PDUFA) action date set for 23 May 2023
Lund, Sweden — 8 Decembe... |
| 23.11.2022 | Camurus announces that Braeburn resubmits NDA for Brixadi™ in the US | Camurus announces that Braeburn resubmits NDA for Brixadi™ in the US
Wed, Nov 23, 2022 21:30 CET Report this content
Lund, Sweden — 23 November 2022 — Camurus AB (NASDAQ STO: CAMX) today announced that its US licensee Braeburn Inc. has resu... |
| 11.11.2022 | Camurus to present at Jefferies 2022 Healthcare Conference London | Camurus to present at Jefferies 2022 Healthcare Conference London
Fri, Nov 11, 2022 08:00 CET Report this content
Lund, Sweden — 11 November 2022 — Camurus (Nasdaq Stockholm; CAMX) announces that Fredrik Tiberg, President and CEO, will pres... |
| 10.11.2022 | Camurus’ Interim Report Third Quarter 2022 | Camurus’ Interim Report Third Quarter 2022
Thu, Nov 10, 2022 07:00 CET Report this content
“The third quarter was financially Camurus’ best quarter to date”
Third quarter summary
July - September Total revenues amounted to SEK 241 (154) mil... |
| 06.09.2022 | Camurus presenting five-year vision for growth and financial outlook at Capital Markets and R&D Day | Camurus presenting five-year vision for growth and financial outlook at Capital Markets and R&D Day
Tue, Sep 06, 2022 08:33 CET Report this content
Lund, Sweden — 6 September 2022 — Camurus (NASDAQ STO: CAMX) is today hosting a Capital ... |
| 31.08.2022 | Update of change in number of shares and votes in Camurus | Update of change in number of shares and votes in Camurus
Wed, Aug 31, 2022 20:00 CET Report this content
Lund, Sweden — 31 August 2022 — After the announcement earlier today regarding the change in the number of shares and votes in Camurus... |
| 31.08.2022 | Change in number of shares and votes in Camurus | Change in number of shares and votes in Camurus
Wed, Aug 31, 2022 07:00 CET Report this content
Lund, Sweden — 31 August 2022 — During August 2022, 298,700 subscription warrants in Camurus’ subscription warrant series TO2019/2022 have been ... |
| 26.08.2022 | Program for Camurus’ Capital Markets and R&D Day 6 September 2022 | Program for Camurus’ Capital Markets and R&D Day 6 September 2022
Fri, Aug 26, 2022 18:00 CET Report this content
Lund, Sweden — 26 August 2022 — Camurus (NASDAQ STO: CAMX) announce that the program for the company’s Capital Markets and... |
| 23.08.2022 | Exercise of Camurus’ subscription warrant program 2019/2022 | Exercise of Camurus’ subscription warrant program 2019/2022
Tue, Aug 23, 2022 07:00 CET Report this content
Lund, Sweden — 23 August 2022 — During August 2022, a total of 301,200 subscription warrants in Camurus AB’s warrant program 2019/20... |
| 15.07.2022 | Camurus’ Interim Report Second Quarter 2022 | Camurus’ Interim Report Second Quarter 2022
Fri, Jul 15, 2022 07:00 CET Report this content
“For the first time and ahead of plan, Camurus entered profitability in the second quarter”
Second quarter summary
April - June Total revenues amoun... |
| 08.07.2022 | Solasia acquires episil oral liquid business from Camurus | Solasia acquires episil oral liquid business from Camurus
Fri, Jul 08, 2022 08:30 CET Report this content
Lund, Sweden and Tokyo, Japan — 8 July 2022 — Camurus AB (NASDAQ STO: CAMX, hereinafter “Camurus”) and Solasia Pharma K.K. (TSE: 4597,... |
| 30.06.2022 | Change in number of shares and votes in Camurus | Change in number of shares and votes in Camurus
Thu, Jun 30, 2022 07:00 CET Report this content
Lund, Sweden — 30 June 2022 — During June 2022, 37,700 subscription warrants in Camurus’ subscription warrant series TO2019/2022 have been exerc... |
| 10.06.2022 | Invitation to Camurus’ Capital Markets and R&D Day 6 September 2022 | Invitation to Camurus’ Capital Markets and R&D Day 6 September 2022
Fri, Jun 10, 2022 08:00 CET Report this content
Lund, Sweden — 10 June 2022 — Camurus (NASDAQ STO: CAMX) invites investors, analysts and media to a Capital Markets and ... |
| 07.06.2022 | Camurus to present at Jefferies 2022 Healthcare Conference New York | Camurus to present at Jefferies 2022 Healthcare Conference New York
Tue, Jun 07, 2022 08:00 CET Report this content
Lund, Sweden — 7 June 2022 — Camurus (Nasdaq Stockholm; CAMX) announces that Fredrik Tiberg, President and CEO, will present... |
| 31.05.2022 | Change in number of shares and votes in Camurus | Change in number of shares and votes in Camurus
Tue, May 31, 2022 16:00 CET Report this content
Lund, Sweden — 31 May 2022 — During May 2022, 140,659 subscription warrants in Camurus’ subscription warrant series TO2019/2022 have been exerci... |
| 12.05.2022 | Resolutions at the annual general meeting 2022 in Camurus | Resolutions at the annual general meeting 2022 in Camurus
Thu, May 12, 2022 19:15 CET Report this content
Lund, Sweden — 12 May 2022 — Camurus AB’s (CAMX) annual general meeting 2022 was held today, Thursday 12 May, at Elite Hotel Ideon in ... |
| 12.05.2022 | Camurus' Interim Report January-March 2022 | Camurus' Interim Report January-March 2022
Thu, May 12, 2022 07:00 CET Report this content
"Camurus had a strong start of the year with results heading in the direction of long-term profitability."
Summary first quarter 2022 Total... |
| 06.04.2022 | Camurus Annual Report for 2021 | Camurus Annual Report for 2021
Wed, Apr 06, 2022 10:00 CET Report this content
Lund, Sweden — 6 April 2021 — Camurus (CAMX) today announces that the Annual Report for 2021 now is available at the company’s website: www.camurus.com, and as a... |
| 06.04.2022 | Notice of annual general meeting 2022 in Camurus AB (publ) | Notice of annual general meeting 2022 in Camurus AB (publ)
Wed, Apr 06, 2022 07:00 CET Report this content
The shareholders of Camurus AB (publ), Reg. No 556667-9105, are hereby invited to the Annual General Meeting (“AGM”) on 12 May 2022 a... |
| 16.02.2022 | Camurus’ Full Year Report 2021 | Camurus’ Full Year Report 2021
Wed, Feb 16, 2022 07:00 CET Report this content
“Strong fourth quarter, with record sales, new regulatory submission and good progress in our pipeline and partnerships”
Fourth quarter and full year summary
Oct... |
| 13.01.2022 | Camurus announces dosing initiated in Phase 3 trial of weekly setmelanotide in patients with genetic obesity disorder | Camurus announces dosing initiated in Phase 3 trial of weekly setmelanotide in patients with genetic obesity disorder Thu, Jan 13, 2022 16:30 CET
Lund, Sweden — 13 January 2022 — Camurus (NASDAQ STO: CAMX) today announces that the company’s... |
| 13.01.2022 | Camurus announces dosing initiated in Phase 3 trial of weekly setmelanotide in patients with genetic obesity disorder | Lund, Sweden - 13 January 2022 - Camurus (NASDAQ STO: CAMX) today announces that the company's license partner Rhythm Pharmaceuticals has dosed the first patients in a Phase 3 trial evaluating weekly setmelanotide subcutaneous depot in pati... |
| 30.12.2021 | Change in number of shares and votes in Camurus | Change in number of shares and votes in Camurus Thu, Dec 30, 2021 14:30 CET
Lund, Sweden — 30 December 2021 — As a result of 207,667 subscription warrants being exercised within Camurus’ subscription warrant series TO2018/2021, the number o... |
| 16.12.2021 | Braeburn receives new Complete Response Letter for Brixadi in the US | Lund, Sweden -- 15 December 2021 -- Camurus AB (NASDAQ STO: CAMX) today announced that its US licensee Braeburn has received a Complete Response Letter (CRL) from the US Food and Drug Administration (FDA) for its updated New Drug Applicatio... |
| 15.12.2021 | Braeburn receives new Complete Response Letter for Brixadi in the US | Braeburn receives new Complete Response Letter for Brixadi in the US Wed, Dec 15, 2021 23:00 CET
Lund, Sweden — 15 December 2021 — Camurus AB (NASDAQ STO: CAMX) today announced that its US licensee Braeburn has received a Complete Response ... |
| 30.11.2021 | The European Medicines Agency accepts application to extend the Buvidal indication to include treatment of chronic pain | The European Medicines Agency accepts application to extend the Buvidal indication to include treatment of chronic pain Tue, Nov 30, 2021 08:00 CET
Sweden — 30 November 2021 — Camurus (NASDAQ STO: CAMX) today announces that the European Med... |
| 30.11.2021 | The European Medicines Agency accepts application to extend the Buvidal indication to include treatment of chronic pain | Sweden -- 30 November 2021 -- Camurus (NASDAQ STO: CAMX) today announces that the European Medicines Agency (EMA) has accepted the company's submission of a Type II variation application for Buvidal® (buprenorphine) prolonged release inject... |
| 11.11.2021 | Camurus announces dosing initiated in Phase 3 study of CAM2029 in patients with neuroendocrine tumors | Lund, Sweden -- 11 November 2021 -- Camurus (NASDAQ STO: CAMX) today announces that dosing has been initiated in the company's randomized, active-controlled Phase 3 study, SORENTO, which aims to evaluate the efficacy and safety of octreotid... |
| 11.11.2021 | Camurus announces dosing initiated in Phase 3 study of CAM2029 in patients with neuroendocrine tumors | Camurus announces dosing initiated in Phase 3 study of CAM2029 in patients with neuroendocrine tumors Thu, Nov 11, 2021 14:00 CET
Lund, Sweden — 11 November 2021 — Camurus (NASDAQ STO: CAMX) today announces that dosing has been initiated in... |
| 04.11.2021 | Camurus’ Interim Report Third Quarter 2021 | Camurus’ Interim Report Third Quarter 2021 Thu, Nov 04, 2021 07:00 CET
“Solid third quarter with continued progress in our development pipeline, double-digit quarterly sales growth and strong results development”
Summary third quarter 2021
... |
| 27.10.2021 | Camurus’ Nomination Committee appointed for the Annual General Meeting 2022 | Camurus’ Nomination Committee appointed for the Annual General Meeting 2022 Wed, Oct 27, 2021 07:00 CET
Lund — 27 October 2021 — Camurus today announced that the Nomination Committee for the Annual General Meeting, AGM, 2022 consists of the... |
| 13.10.2021 | Camurus : appoints Jon U. Garay Alonso as Chief Financial Officer | Lund, Sweden - 13 October 2021 - Camurus (NASDAQ STO: CAMX) today announces the appointment of Jon U.
Garay Alonso as the new Chief Financial Officer (CFO), and a member of Camurus' Management Team, effective from 1 February 2022.
Jon bring... |
| 13.10.2021 | Camurus appoints Jon U. Garay Alonso as Chief Financial Officer | Camurus appoints Jon U. Garay Alonso as Chief Financial Officer Wed, Oct 13, 2021 17:00 CET
Lund, Sweden — 13 October 2021 — Camurus (NASDAQ STO: CAMX) today announces the appointment of Jon U. Garay Alonso as the new Chief Financial Office... |
| 30.09.2021 | Change in number of shares and votes in Camurus | Change in number of shares and votes in Camurus Thu, Sep 30, 2021 07:00 CET
Lund, Sweden — 30 September 2021 — During September 2021, 31,100 subscription warrants in Camurus’ subscription warrant series TO2018/2021 have been exercised and a... |
| 16.09.2021 | FDA grants Orphan Drug Designation in the US for CAM2029 for the treatment of polycystic liver disease | FDA grants Orphan Drug Designation in the US for CAM2029 for the treatment of polycystic liver disease Thu, Sep 16, 2021 11:00 CET
Lund, Sweden — 16 September 2021 — Camurus (NASDAQ STO: CAMX) today announced that the US Food and Drug Admin... |
| 15.09.2021 | Camurus' : Chief Financial Officer (CFO) will leave the company | Lund, Sweden - 15 September 2021 - Camurus (NASDAQ STO: CAMX) today announced that
Eva Pinotti-Lindqvist has decided to leave her position in the company. The company has initiated a process to recruit a successor. Eva has held her position... |
| 15.09.2021 | Camurus’ Chief Financial Officer (CFO) will leave the company | Camurus’ Chief Financial Officer (CFO) will leave the company Wed, Sep 15, 2021 09:00 CET
Lund, Sweden — 15 September 2021 — Camurus (NASDAQ STO: CAMX) today announced that Eva Pinotti-Lindqvist has decided to leave her position in the comp... |
| 31.08.2021 | Change in number of shares and votes in Camurus | Change in number of shares and votes in Camurus Tue, Aug 31, 2021 07:00 CET
Lund, Sweden — 31 August 2021 — During August 2021, 27,300 subscription warrants in Camurus’ subscription warrant series TO2018/2021 have been exercised and as a co... |
| 15.07.2021 | Camurus’ Interim Report Second Quarter 2021 | Camurus’ Interim Report Second Quarter 2021 Thu, Jul 15, 2021 07:00 CET
“Significant progress on key objectives with increasing revenues, new regulatory approvals, and a potential US market authorization in 2021”
Summary second quarter 2021... |
| 28.06.2021 | Camurus : 2021-06-26 Camurus announces PDUFA date for Brixadi for the treatment of opioid use disorder in the US | PRESS RELEASE
Camurus announces PDUFA date for Brixadi for the treatment of opioid use disorder in the US
New PDUFA action date for Brixadi set for 15 December 2021
Lund, Sweden - 26 June 2021 - Camurus (NASDAQ STO: CAMX) announced today th... |
| 26.06.2021 | Camurus announces PDUFA date for Brixadi for the treatment of opioid use disorder in the US | LUND, Sweden, June 26, 2021 /PRNewswire/ -- Camurus (NASDAQ STO: CAMX) announced today that the New Drug Application (NDA) by Camurus' US licensee Braeburn for Brixadi™ (buprenorphine) extended-release weekly and monthly injection for subcu... |
| 26.06.2021 | Camurus : announces PDUFA date for Brixadi for the treatment of opioid use disorder in the US | New PDUFA action date for Brixadi set for 15 December 2021
Lund, Sweden - 26 June 2021 - Camurus (NASDAQ STO: CAMX) announced today that the New Drug Application (NDA) by Camurus' US licensee Braeburn for Brixadi™ (buprenorphine) extended-r... |
| 26.06.2021 | Camurus announces PDUFA date for Brixadi for the treatment of opioid use disorder in the US | New PDUFA action date for Brixadi set for 15 December 2021
LUND, Sweden, June 26, 2021 /PRNewswire/ -- Camurus (NASDAQ STO: CAMX) announced today that the New Drug Application (NDA) by Camurus' US licensee Braeburn for Brixadi™ (buprenorphi... |
| 16.06.2021 | CAMURUS AB (PUBL)
Camurus : 2021-06-15 Camurus announces Braeburn resubmits New Drug Application for Brixadi™ in the US | Lund, Sweden - 15 June2021 -Camurus AB (NASDAQ STO: CAMX) today announced that its US licensee Braeburn has resubmitted the New Drug Application (NDA) for Brixadi1(buprenorphine) extended-release weekly and monthly injections for the treatm... |
| 16.06.2021 | CAMURUS AB (PUBL)
Camurus : announces Braeburn resubmits New Drug Application for Brixadi™ in the US | Lund, Sweden - 15 June 2021 - Camurus AB (NASDAQ STO: CAMX) today announced that its US licensee Braeburn has resubmitted the New Drug Application (NDA) for Brixadi1 (buprenorphine) extended-release weekly and monthly injections for the tre... |
| 31.05.2021 | Change in number of shares and votes in Camurus | Change in number of shares and votes in Camurus Mon, May 31, 2021 07:00 CET
Lund, Sweden — 31 May 2021 — During May 2021, 239,250 subscription warrants in Camurus’ subscription warrant series 2018/2021 have been exercised and as a consequen... |
| 21.05.2021 | CAMURUS AB (PUBL)
Camurus : Exercise of Camurus' subscription warrant program 2018/2021 | Lund, Sweden -- 21 May 2021 -- On 15 May 2021, the subscription period in Camurus AB's (publ) ("Camurus") subscription warrant program 2018/2021 started. In a first cashless exercise 260,782 shares, out of the program's total 607,... |
| 21.05.2021 | CAMURUS AB (PUBL)
Camurus : 2021-05-21 Exercise of Camurus' subscription warrant program 2018/2021 | PRESS RELEASE
Exercise of Camurus' subscription warrant program 2018/2021
Lund, Sweden - 21 May 2021 - On 15 May 2021, the subscription period in Camurus AB's (publ) ("Camurus") subscription warrant program 2018/2021 started. In a... |
| 21.05.2021 | Exercise of Camurus’ subscription warrant program 2018/2021 | Exercise of Camurus’ subscription warrant program 2018/2021 Fri, May 21, 2021 10:00 CET
Lund, Sweden — 21 May 2021 — On 15 May 2021, the subscription period in Camurus AB’s (publ) (“Camurus”) subscription warrant program 2018/2021 started. ... |
| 19.05.2021 | Camurus receives Carnegie Sustainability Award 2021 | Camurus receives Carnegie Sustainability Award 2021 Wed, May 19, 2021 14:00 CET
Lund, Sweden — 19 May 2021 — Camurus (NASDAQ STO: CAMX) announces today that the company has been awarded with the Carnegie Sustainability Award 2021 in the cat... |
| 14.04.2021 | CAMURUS AB (PUBL)
Camurus : Annual Report for 2020 | Lund, Sweden - 14 April 2021 - Camurus (CAMX) today announces that the Annual Report for 2020 now is available at the company's website: www.camurus.com.
For more information
Fredrik Tiberg, President & CEO
Tel. +46 (0)46 286 46 92
fred... |